Showing results (1-10 of 19) with videos related to

Sort By:
Pageof 2
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 24, 2017
Achieving Precision Death with Cell-Cycle Inhibitors that Target DNA Replication and RepairAimee Bence Lin, Samuel C McNeely, Richard P Beckmann
Toxicology and Applied Pharmacology|May 27, 2008
Mitotic arrest-associated apoptosis induced by sodium arsenite in A375 melanoma cells is BUBR1-dependentSamuel C McNeely, B Frazier Taylor, J Christopher States
Toxicology and Applied Pharmacology|May 20, 2008
Arsenite-induced mitotic death involves stress response and is independent of tubulin polymerizationB Frazier Taylor, Samuel C McNeely, Heather L Miller, et al.
Environmental Health Perspectives|September 13, 2006
Exit from arsenite-induced mitotic arrest is p53 dependentSamuel C McNeely, Xiaogiang Xu, B Frazier Taylor, et al.
Chemical Research in Toxicology|December 17, 2009
Suppression of p53 and p21CIP1/WAF1 reduces arsenite-induced aneuploidyAna María Salazar, Heather L Miller, Samuel C McNeely, et al.
The Journal of Pharmacology and Experimental Therapeutics|April 15, 2006
p53 suppression of arsenite-induced mitotic catastrophe is mediated by p21CIP1/WAF1B Frazier Taylor, Samuel C McNeely, Heather L Miller, et al.
Toxicology and Applied Pharmacology|March 11, 2008
Sensitivity to sodium arsenite in human melanoma cells depends upon susceptibility to arsenite-induced mitotic arrestSamuel C McNeely, Alex C Belshoff, B Frazier Taylor, et al.
Toxicology and Applied Pharmacology|April 24, 2002
Arsenite disrupts mitosis and induces apoptosis in SV40-transformed human skin fibroblastsJ Christopher States, John J Reiners, Joel G Pounds, et al.
Molecular Cancer Therapeutics|June 2, 2012
The checkpoint kinase inhibitor AZD7762 potentiates chemotherapy-induced apoptosis of p53-mutated multiple myeloma cellsHeather J Landau, Samuel C McNeely, Jayasree S Nair, et al.
The Oncologist|August 2, 2023
A Phase I Dose-Escalation Study of LY3405105, a Covalent Inhibitor of Cyclin-Dependent Kinase 7, Administered to Patients With Advanced Solid TumorsElena Garralda, Alison M Schram, Philippe L Bedard, et al.
Pageof 2